2-iminobiotin - Neurophyxia

Drug Profile

2-iminobiotin - Neurophyxia

Alternative Names: 2-IB; 2-Iminobiotin; Neufix

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurophyxia
  • Developer Neurophyxia; University Medical Center Utrecht
  • Class Imidazoles; Neuroprotectants; Pentanoic acids; Small molecules
  • Mechanism of Action Nitric oxide synthase type I inhibitors; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asphyxia

Most Recent Events

  • 28 Sep 2017 University Medical Centre Utrecht and Neurophyxia completes a phase II trial in Asphyxia (In infants) in Netherlands (IV), before September 2017 (EudraCT2014-004265-25)
  • 23 May 2017 Neurophyxia terminates a phase II trial in Asphyxia (In neonates) because recruitment too slow and site decided to use hypothermia (exclusion criteria) in Turkey and Lithuania (IV) (NCT01626924)
  • 14 Sep 2016 Phase-II clinical trials in Asphyxia (In neonates) in Congo (IV) (EudraCT2015-003063-12)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top